MedBen Client Satisfaction Survey

Search

« House Subcommittee Votes To Repeal Medicare Cost Control PanelWomen More Likely To Ignore Heart Attack Warnings »

FDA Requires Statin Labels To Warn Of Diabetes, Memory Risks

02/29/12

  01:16:32 pm, by MedBen5   , 195 words,  
Categories: News, Prescription, Wellness

FDA Requires Statin Labels To Warn Of Diabetes, Memory Risks

Makers of statins must revise their labels to warn about risks of elevated blood sugar levels – a cause of type 2 diabetes – and memory loss, HealthDay reports. The Food and Drug Administration made the announcement, but also stressed that the benefits of the cholesterol-lowering drugs far outweigh the potential dangers.

“We want health-care professionals and patients to have the most current information on the risks of statins, but also to assure them that these medications continue to provide an important health benefit of lowering cholesterol,” Dr. Mary Parks, director of the FDA’s Division of Metabolism and Endocrinology Products, said in a news release. The agency made the change following recent clinical trials and isolated reports of side effects.

The full list of statins include: Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Combination products include: Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe), the FDA said.

Statins are popularly precribed to patients who have high cholesterol or at risk for fatal and non-fatal cardiovascular events. Healthy individuals with one or more cardiovascular risk factors can also benefit from the drug.

No feedback yet